Dear Editor,

*RHD* and *RHCE*, encoding Rhesus proteins, are highly homologous genes located adjacently on the same chromosome (chromosome 1). Therefore, hybrid *RHD* genes, in which some portions are substituted with the *RHCE* sequence can change the extracellular loop of the RhD antigen, leading to variable reactivity to anti-D reagents \[[@B1]\].

Partial D phenotypes have historically been classified using epitope studies \[[@B2]\] and, recently, using genetic studies. DBS is a partial D phenotype characterized by c.\[676G\>C\]+\[697G\>C\] (NM_016124.4) and has been named based on its positive reactivity with the D monoclonal antibodies (MoAbs) BS228 and BS233 (Biotest, Dreieich, Germany) \[[@B3]\]. Three DBS subtypes have been reported till date: *DBS-0* \[[@B1]\], *DBS-1* \[[@B3][@B4]\], and *DBS-2* \[[@B5]\]. Molecular studies have identified *DBS-1* in an Arabian \[[@B3]\] and a Japanese family \[[@B4]\]; however, it is unknown whether *DBS-1* correlates with the same hybrid gene of a single evolutionary origin in other, unrelated individuals from different ethnic groups. To the best of our knowledge, this is the first report of a *DBS-1* case in a Korean family. This study was approved by the Institutional Review Board of Samsung Medical Center, Seoul, Korea (SMC-2019-11-160), and written informed consent was obtained from the proband and all family members.

The proband was a Korean woman with fibrocystic breast changes, who was admitted to the Samsung Medical Center. D typing using anti-D Bioclone (MAD2 clone; Ortho Clinical Diagnostics, Raritan, NJ, USA) was negative. Weak D testing using anti-D Bioclone and human IgG/IgM monoclonal anti-D (Millipore, Livingston, UK) yielded a result of grade 2+, while the result of partial D testing using D-screen (Diagast, Loos, France) was consistent with *DBS-1*. The phenotypes of the current case and previously reported DBS cases are summarized in [Table 1](#T1){ref-type="table"}.

The RhCE phenotype was ccEe (anti-C, -c, -E, and -e antibodies were obtained from Bioclone, Ortho Clinical Diagnostics, Buckinghamshire, UK), and *RHD* genotyping was carried out according to a previously described method \[[@B6]\]. Exon 5 was not amplified by the primer sets used in this study, but the region from exon 4 to exon 6 was amplified and the PCR product was sequenced using *RHCE* exon 5-specific primers; the Rhesus box was also PCR-amplified ([Fig. 1A](#F1){ref-type="fig"}). The proband harbored a hybrid *RHD-cE(5)-D* (*DBS/d*) allele involving the following amino acid changes: F223V, A226P, E233Q, V238M, V245L, G263R, and K267M. *RHD* genotypes of other family members are shown in [Fig. 1B](#F1){ref-type="fig"}. The breakpoints were confirmed between exon 4 and exon 6 by intron analysis \[[@B3][@B4]\]. The 5′ breakpoint region was the same as that reported by Omi, et al. \[[@B4]\], whereas the 3′ breakpoint region was novel ([Fig. 1C](#F1){ref-type="fig"}).

In various partial D phenotypes, such as DIIIa, DVa, DVI, DAR, DFR, DBT, and DBS, *RHD* exon 5 is substituted with a part of *RHCE* exon 5 \[[@B7]\]. Exon 5 is predicted to encode the fourth extracellular loop of the D polypeptide. In DBS, the coexistence of two amino acid changes (A226P and E233Q) caused by c.676G\>C and c.697G\>C point variants is required for the characteristic phenotype \[[@B4]\]. A226P is observed in the fourth loop of antigen E \[[@B4]\] and is thought to have a considerable effect on D antigen density \[[@B1]\]. E233Q is also observed in the fourth loop as part of D^w^ (RH23) \[[@B8]\]. *DBS-1* and *-2*, which share F223V, A226P, and E233Q, exhibited different reactivity to the MoAbs P3X249, P3X290, and P3X21211F1 (*DBS-1*, +/+/− and *DBS-2*, −/−/trace). This difference might have been caused by the change in the extracellular amino acid, V238M, which is found in *DBS-0* and *DBS-1*, but not in *DBS-2*. Other amino acid changes observed in *DBS-1*, including V245L, G263R, and K267M, are located in the intracellular or transmembrane regions; however, they might affect the RhD phenotype.

The genetic basis of the RhD blood group differs across races and ethnicities. For example, the RhD-negative phenotype mainly results from *RHD* deletion in Caucasians, whereas *RHD* alterations, such as *RHD^\*^D-CE*(4-7)*-D*, are common in Africans \[[@B9]\]. Asians exhibit a high prevalence of c.1227G\>A (NM_016124.4), known as "Asia type DEL." These ethnicity-specific trends are used not only to diagnose RhD variants, but also for transfusion protocols \[[@B10]\]. The 3′ breakpoint observed in our case differed from that found in a Japanese family \[[@B4]\], suggesting that the *DBS-1* cases have different genetic origins.

In conclusion, we reported the first case of *DBS-1* in a Korean family. To understand the RhD characteristics specific to Korean ethnicity, further evaluation of RhD variants is required.
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![Results of the genetic analysis of the proband and her family members. (A) Long-range PCR with primers located in non-Rhesus box sequences. A 2,778-bp fragment was amplified by PCR, indicating the presence of a hybrid *RHD* gene (lanes I-1, II-1, and II-2). (B) Pedigree, Rh phenotypes, and *RHD* genotypes of the Korean DBS-1 family. The genotypes and phenotypes of the DBS-1 family were determined using combined data from sequencing analysis, hybrid Rhesus box PCR, and serological analysis. Black circles indicate the DBS-1 phenotype. The proband is indicated by a black arrow. Total *RHD* deletion is denoted as "*d*" in the genotype. (C) Part of the *RHD* nucleotide sequence in DBS reported by Wagner, et al. \[[@B3]\] and this case. In both cases, the 5′ breakpoint region was located between the *RHD*-specific c.642-249T and the first *RHCE*-specific nucleotide, c.667G (blue arrow). The 3′ breakpoint region, located between the last *RHCE*-specific nucleotide and the first *RHD*-specific nucleotide of intron 5, differed for each case; it was located between c.800 and c.801+101 in the case reported by Wagner, et al. \[[@B3]\] and between c.801+1463 and c.801+1505 in the current case (white arrow).](alm-40-337-g001){#F1}

###### Comparison of serologic characteristics based on analysis using MoAbs between previous DBS cases and the present DBS case. Partial D testing was performed using D-screen (Diagast, Loos, France)

![](alm-40-337-i001)

  Type        RhD phenotype   RhCE phenotype   Ethnicity   Reference                                                                                          
  ----------- --------------- ---------------- ----------- ----------- ----- ----- ----- ----- ---------- ---------- ------- ---------- ----------- --------- ---------------
  DBS-0                       NA               NA          NA          NA    NA    NA    NA    NA         NA         NA      NA         CDe         NA        \[[@B1]\]
  DBS-1                       Pos              Pos         Neg         Neg   Neg   Neg   Neg   Neg (IS)   Neg (IS)   Neg     Pos        cDE         Korean    Current study
  Pos (AHG)   Pos (AHG)                                                                                                                                       
  Pos (1+)    Pos (3+)        Neg              Neg         Neg         Neg   Neg   NA    NA    Neg        Pos (2+)   cDE     Arabian    \[[@B3]\]             
  Pos (1+)    NA              Neg              Neg         NA          Neg   NA    NA    NA    Neg        Pos (1+)   cDE     Japanese   \[[@B4]\]             
  DBS-2                       Neg              Neg         Neg         Neg   Neg   Neg   Neg   NA         NA         Trace   Pos (1+)   cDE         Chinese   \[[@B5]\]

^\*^The results using human IgG/IgM monoclonal anti-D (Millipore, Livingston, UK); ^†^The results using anti-D Bioclone (MAD2 clone; Ortho Clinical Diagnostics, Raritan, NJ, USA).

Abbreviations: ep, epitope; MoAbs, monoclonal antibodies; IS, immediate spin; AHG, antihuman globulin; Pos, positive; Neg, negative; NA, not available.

[^1]: ^\*^These authors equally contributed to this study.
